CYT(Delisted)
Cyteir TherapeuticsยทNASDAQ
--
--(--)
CYT Profile
Cyteir Therapeutics, Inc.
128 Spring St, Building A, Suite 510, Lexington, MA 02421
--
Cyteir Therapeutics, Inc., was established on June 4, 2012 as a Delaware corporation. They are a clinical-stage biotechnology company focused on developing and commercializing next-generation precision oncology drugs that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality is a clinically validated method of drug development that occurs when either of the two conditions is deficient, which are tolerable in cells alone but fatal together. Their main project, CYT-0851, along with the next-generation drug candidate CYT-1853, utilizes a new function to obtain a synthetic lethal relationship, namely the relationship between the overexpression of cytidine deaminases (CDs) in the DNA damage gene family and the functional inhibition of homologous recombination (HR), a DNA repair pathway that is crucial for the survival of some cancers.
